Against blindness with eye functional factors
The biotech pharma to Re-developing eye sight with retinal disease medicine
Against blindness with eye functional factors
The biotech pharma to Re-developing eye sight with retinal disease medicine
About Us
About PaRxVision
As a startup biotech pharma company, PaRxVision is focused on developing solutions for retinal diseases. The company is engaged in researching and developing new drugs, as well as optimizing eye drop drug delivery methods such as eye drops, to treat retinal diseases. The ultimate goal of PaRxVision is to be to bring a safe and effective retinal disease medicine to market that can improve the lives of patients suffering from retinal diseases. To achieve this goal, the company conducts research to evaluate the safety and efficacy of its products, as well as seeks partnerships with other companies or investors to further support its research and development efforts.
The Science
Para-Transcription Factor (PTF) stands out as a distinctive transcription factor capable of being secreted and penetrating neighboring cells, marking a departure from conventional cell signaling pathways characterized by intracellular cascades. While these traditional pathways have long served as invaluable guides for selecting drug targets, the emergence of the PTF signaling pathway presents a fresh perspective. This novel mechanism not only offers new insights but also unlocks promising avenues for drug development and innovative drug delivery strategies. At the forefront of harnessing the potential of PTFs, PaRxVision is dedicated to pioneering more effective and precise therapies for retinal diseases.
Our Technology
Our approach is focused on two key aspects: protein movement between cells and targeting specific molecular pathways involved in retinal development and maintenance. By leveraging these two factors, we aim to develop more effective drug delivery methods and identify novel drugs that can address the underlying mechanisms of retinal diseases. If successful, our technology and drug discovery approach could have a significant impact on the field of ophthalmology and improve outcomes for patients with retinal diseases. Developing more targeted and effective treatments could help to alleviate the burden of retinal diseases and improve the quality of life for patients.
The First Project
To develop eye drop formulation for ocular drug delivery based on the new understanding of protein movement between cells.
Let's see a future without needles!